0001809122 2022-01-01 2022-06-30 0001809122 cvac:VirtualSharesProgramIiMember 2021-04-01 2021-09-30 0001809122 cvac:IfrsCashAndCashEquivalentsMember ifrs-full:CurrencyRiskMember currency:USD 2022-06-30 0001809122 cvac:IfrsCashAndCashEquivalentsMember ifrs-full:CurrencyRiskMember currency:CHF 2022-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-01-01 2021-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-01-01 2021-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-01-01 2021-06-30 0001809122 cvac:BoehringerIngelheimMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-01-01 2021-06-30 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2022-01-01 2022-06-30 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2022-01-01 2022-06-30 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2021-01-01 2021-06-30 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2021-01-01 2021-06-30 0001809122 country:NL cvac:GenmabMember 2022-01-01 2022-06-30 0001809122 country:CH cvac:CrisprMember 2022-01-01 2022-06-30 0001809122 country:BE cvac:GlaxosmithklineMember 2022-01-01 2022-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2022-01-01 2022-06-30 0001809122 cvac:ResearchAndDevelopmentServicesMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsProductMember 2022-01-01 2022-06-30 0001809122 country:NL cvac:GenmabMember 2021-01-01 2021-06-30 0001809122 country:DE cvac:BoehringerIngelheimMember 2021-01-01 2021-06-30 0001809122 country:CH cvac:CrisprMember 2021-01-01 2021-06-30 0001809122 country:BE cvac:GlaxosmithklineMember 2021-01-01 2021-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2021-01-01 2021-06-30 0001809122 cvac:ResearchAndDevelopmentServicesMember 2021-01-01 2021-06-30 0001809122 cvac:IfrsProductMember 2021-01-01 2021-06-30 0001809122 cvac:VincentStphenneMember 2022-01-01 2022-06-30 0001809122 cvac:BaronJeanStephenneMember 2022-01-01 2022-06-30 0001809122 2022-06-01 2022-06-30 0001809122 cvac:IfrsLineOfCreditMember 2021-01-01 2021-06-30 0001809122 ifrs-full:PreferenceSharesMember 2022-06-30 0001809122 ifrs-full:OrdinarySharesMember 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ExecutiveBoardMembersMember 2022-06-22 2022-06-22 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefDevelepmentOfficerMember 2021-08-01 2021-08-01 0001809122 cvac:LongTermIncentivePlanMember srt:ChiefOperatingOfficerMember 2021-07-01 2021-07-01 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember 2020-12-01 2020-12-01 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefScientificOfficerMember 2020-11-16 2020-11-16 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefScientificOfficerMember 2022-05-01 2022-05-31 0001809122 cvac:VirtualSharesProgramIiMember 2022-06-30 0001809122 cvac:ThenChiefExecutiveOfficerMember 2022-06-22 2022-06-22 0001809122 cvac:SupervisoryBoardMembersMember 2022-06-22 2022-06-22 0001809122 cvac:ExecutiveBoardMembersMember 2022-06-22 2022-06-22 0001809122 srt:ChiefOperatingOfficerMember 2022-02-10 2022-02-10 0001809122 cvac:LongTermIncentivePlanMember cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember 2021-12-23 2021-12-23 0001809122 cvac:LongTermIncentivePlanMember cvac:SupervisoryBoardMembersMember 2021-06-24 2021-06-24 0001809122 cvac:MilestonesMember ifrs-full:TopOfRangeMember 2022-06-30 0001809122 cvac:MilestonesMember ifrs-full:BottomOfRangeMember 2022-06-30 0001809122 2022-06-08 0001809122 ifrs-full:TreasurySharesMember 2021-01-01 2021-06-30 0001809122 ifrs-full:IssuedCapitalMember 2022-01-01 2022-06-30 0001809122 ifrs-full:IssuedCapitalMember 2021-01-01 2021-06-30 0001809122 cvac:GermanFederalMinistryOfEducationAndResearchMember 2022-06-30 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2022-06-30 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2022-06-30 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2021-12-31 0001809122 cvac:BillAndMelindaGatesFoundationBmgfMember 2021-12-31 0001809122 cvac:GermanFederalMinistryOfEducationAndResearchMember 2021-06-30 0001809122 ifrs-full:TreasurySharesMember 2022-06-30 0001809122 ifrs-full:RetainedEarningsMember 2022-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-06-30 0001809122 ifrs-full:IssuedCapitalMember 2022-06-30 0001809122 ifrs-full:CapitalReserveMember 2022-06-30 0001809122 ifrs-full:TreasurySharesMember 2021-12-31 0001809122 ifrs-full:RetainedEarningsMember 2021-12-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001809122 ifrs-full:IssuedCapitalMember 2021-12-31 0001809122 ifrs-full:CapitalReserveMember 2021-12-31 0001809122 ifrs-full:TreasurySharesMember 2021-06-30 0001809122 ifrs-full:RetainedEarningsMember 2021-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-06-30 0001809122 ifrs-full:IssuedCapitalMember 2021-06-30 0001809122 ifrs-full:CapitalReserveMember 2021-06-30 0001809122 ifrs-full:RetainedEarningsMember 2020-12-31 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001809122 ifrs-full:IssuedCapitalMember 2020-12-31 0001809122 ifrs-full:CapitalReserveMember 2020-12-31 0001809122 cvac:CurevacSwissAgMember ifrs-full:UnusedTaxLossesMember 2022-01-01 2022-06-30 0001809122 cvac:CurevacCorporateServiceGmbhMember ifrs-full:UnusedTaxLossesMember 2022-01-01 2022-06-30 0001809122 cvac:CurevacSwissAgMember ifrs-full:TemporaryDifferenceMember 2021-01-01 2021-06-30 0001809122 cvac:CurevacSwissAgMember 2022-01-01 2022-06-30 0001809122 cvac:CurevacCorporateServiceGmbhMember 2022-01-01 2022-06-30 0001809122 cvac:CurevacCorporateServiceGmbhMember 2021-01-01 2021-06-30 0001809122 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-06-30 0001809122 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001809122 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-06-30 0001809122 cvac:BepharbelManufacturingS.aMember 2022-05-01 2022-05-31 0001809122 ifrs-full:TopOfRangeMember 2022-06-30 0001809122 ifrs-full:BottomOfRangeMember 2022-06-30 0001809122 2021-06-30 0001809122 2020-12-31 0001809122 ifrs-full:GrossCarryingAmountMember 2022-01-01 2022-06-30 0001809122 ifrs-full:ConstructionInProgressMember 2022-01-01 2022-06-30 0001809122 cvac:EquipmentPhysicallyLocatedAtCmoFacilitiesMember 2022-01-01 2022-06-30 0001809122 cvac:CompanyOwnedGmpIvFacilityMember 2022-01-01 2022-06-30 0001809122 ifrs-full:GrossCarryingAmountMember cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember 2021-01-01 2021-06-30 0001809122 ifrs-full:GrossCarryingAmountMember cvac:LicensesSoftwareAndPrepaymentsMember 2022-01-01 2022-06-30 0001809122 ifrs-full:GrossCarryingAmountMember cvac:LicensesSoftwareAndPrepaymentsMember 2021-01-01 2021-06-30 0001809122 cvac:FramePharmaceuticalsB.v.AmsterdamNetherlandsMember 2022-06-08 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember ifrs-full:BottomOfRangeMember 2022-06-30 0001809122 cvac:BoehringerIngelheimMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-06-30 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-06-30 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2022-06-30 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2022-06-30 0001809122 cvac:GlaxosmithklineMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-12-31 0001809122 cvac:GenmabMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-12-31 0001809122 cvac:CrisprMember cvac:ResearchServicesCombinedWithIpLicenseMember 2021-12-31 0001809122 cvac:ResearchServicesCombinedWithIpLicenseMember 2021-12-31 0001809122 ifrs-full:CapitalReserveMember 2021-01-01 2021-06-30 0001809122 ifrs-full:TreasurySharesMember 2022-01-01 2022-06-30 0001809122 ifrs-full:CapitalReserveMember 2022-01-01 2022-06-30 0001809122 2021-01-01 2021-12-31 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2022-06-30 0001809122 cvac:DietmarHoppMember 2019-01-01 2019-12-31 0001809122 2022-07-01 2022-07-01 0001809122 cvac:MilestonesMember ifrs-full:TopOfRangeMember 2022-01-01 2022-06-30 0001809122 cvac:MilestonesMember ifrs-full:BottomOfRangeMember 2022-01-01 2022-06-30 0001809122 cvac:MilestonesMember 2022-01-01 2022-06-30 0001809122 cvac:ClarentisSrlMember cvac:AntonyBlancMember 2022-01-01 2022-06-30 0001809122 cvac:SellingAndDistributionExpensesMember 2022-01-01 2022-06-30 0001809122 cvac:SellingAndDistributionExpensesMember 2021-01-01 2021-06-30 0001809122 cvac:LongTermIncentivePlanMember srt:ChiefOperatingOfficerMember 2022-06-30 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ExecutiveBoardMembersMember 2022-06-30 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefDevelepmentOfficerMember 2022-06-30 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefOperatingOfficerAndChiefDevelopmentOfficerMember 2022-03-01 2022-03-01 0001809122 cvac:LongTermIncentivePlanMember cvac:KeyEmployeesMember 2022-03-01 2022-03-01 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2020-05-31 0001809122 cvac:CoalitionForEpidemicPreparednessInnovationsMember 2020-01-31 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsCostOfSalesMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001809122 cvac:IfrsGeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001809122 cvac:IfrsCostOfSalesMember 2021-01-01 2021-06-30 0001809122 cvac:IfrsLineOfCreditMember 2021-06-30 0001809122 cvac:DietmarHoppMember 2020-08-01 2020-08-31 0001809122 cvac:AtMarketOfferingProgramMember 2022-06-01 2022-06-30 0001809122 cvac:IfrsLineOfCreditMember 2021-01-01 2021-12-31 0001809122 cvac:MilestoneRevenuesMember 2022-06-30 0001809122 cvac:VirtualSharesProgramIMember 2022-01-01 2022-06-30 0001809122 cvac:VirtualSharesProgramIiMember 2022-01-01 2022-06-30 0001809122 cvac:RestrictedStockUnitForKeyEmployeesMember 2022-01-01 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember 2022-01-01 2022-06-30 0001809122 cvac:IfrsRestrictedStockUnitMember 2022-01-01 2022-06-30 0001809122 cvac:VirtualSharesProgramIMember 2021-01-01 2021-06-30 0001809122 cvac:VirtualSharesProgramIiMember 2021-01-01 2021-06-30 0001809122 cvac:LongTermIncentivePlanMember 2021-01-01 2021-06-30 0001809122 cvac:IfrsRestrictedStockUnitMember 2021-01-01 2021-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefScientificOfficerMember 2022-01-01 2022-06-30 0001809122 cvac:LongTermIncentivePlanMember cvac:ChiefScientificOfficerMember 2021-01-01 2021-06-30 0001809122 2022-04-01 2022-06-30 0001809122 2022-01-01 2022-03-31 0001809122 cvac:GlaxosmithklineMember 2022-01-01 2022-06-30 0001809122 2022-06-30 0001809122 2022-03-31 0001809122 2021-12-31 0001809122 cvac:ClarentisSrlMember 2021-09-30 0001809122 cvac:AtMarketOfferingProgramMember 2021-09-01 2021-09-30 0001809122 2021-01-01 2021-06-30 0001809122 cvac:MilestoneRevenuesMember 2022-01-01 2022-06-30 iso4217:USD xbrli:shares iso4217:EUR iso4217:USD xbrli:shares cvac:employee cvac:Option xbrli:pure iso4217:EUR xbrli:shares cvac:loan iso4217:CHF

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

​

For the month of August 2022

Commission File Number: 001-39446

​

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

​

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

​

Form 20-F | ⌧ |  | Form 40-F | ☐

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

​

Yes | ☐ |  | No | ⌧

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

​

Yes | ☐ |  | No | ⌧

​

​

​

​

This Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the "SEC") for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac's financial results and business updates as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021; (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management's Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021;

The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

| CUREVAC N.V.
| By: | /s/ Franz-Werner Haas, LLD, LLM
|  | Chief Executive Officer
​ | ​ | ​
​ | ​ | ​
Date: August 18, 2022 | ​ | ​

​

​

​

EXHIBIT INDEX

​

EXHIBIT NO. |  | DESCRIPTION
99.1 |  | Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2022 and for the six months ended June 30, 2022 and 2021
99.2 | ​ | Management’s Discussion and Analysis of Financial Condition and Results of Operations

​

​